Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

JSPR

Jasper Therapeutics Inc

Sep 20 • 04:00PM ET

23.88

Dollar change -0.03
Percentage change -0.13	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO IWC FESM AVSC CANC VTWG

Index	RUT	P/E	-	EPS (ttm)	-5.10	Insider Own	23.35%	Shs Outstand	15.11M	Perf Week	4.97%
Market Cap	360.83M	Forward P/E	-	EPS next Y	-4.15	Insider Trans	-0.05%	Shs Float	11.58M	Perf Month	26.89%
Income	-62.44M	PEG	-	EPS next Q	-1.07	Inst Own	77.42%	Short Float	17.29%	Perf Quarter	7.96%
Sales	0.00M	P/S	-	EPS this Y	32.50%	Inst Trans	5.01%	Short Ratio	10.08	Perf Half Y	-19.51%
Book/sh	6.64	P/B	3.60	EPS next Y	0.53%	ROA	-52.45%	Short Interest	2.00M	Perf Year	209.73%
Cash/sh	7.07	P/C	3.38	EPS next 5Y	-	ROE	-59.32%	52W Range	4.00 - 31.01	Perf YTD	202.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-61.45%	52W High	-22.99%	Beta	2.23
Dividend TTM	-	Quick Ratio	10.79	Sales past 5Y	0.00%	Gross Margin	-	52W Low	497.00%	ATR (14)	1.61
Dividend Ex-Date	-	Current Ratio	10.79	EPS Y/Y TTM	48.65%	Oper. Margin	0.00%	RSI (14)	69.09	Volatility	7.89% 7.90%
Employees	45	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.09	Target Price	71.62
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	33.91%	Payout	-	Rel Volume	2.06	Prev Close	23.91
Sales Surprise	-	EPS Surprise	10.89%	Sales Q/Q	-	Earnings	Aug 13 BMO	Avg Volume	198.53K	Price	23.88
SMA20	15.66%	SMA50	21.74%	SMA200	24.65%	Trades		Volume	409,755	Change	-0.13%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-24	Initiated	JMP Securities	Mkt Outperform	$70
Jul-08-24	Initiated	BTIG Research	Buy	$90
Jun-27-24	Initiated	Stifel	Buy	$86
May-06-24	Initiated	H.C. Wainwright	Buy	$65
Apr-03-24	Initiated	Evercore ISI	Outperform	$65
Mar-28-24	Initiated	RBC Capital Mkts	Outperform	$70
Mar-18-24	Initiated	TD Cowen	Outperform
Aug-11-23	Initiated	CapitalOne	Overweight	$7
Feb-28-22	Initiated	Cantor Fitzgerald	Overweight	$10
Nov-08-21	Initiated	Credit Suisse	Outperform	$15
Oct-21-21	Initiated	William Blair	Outperform
Oct-20-21	Initiated	BMO Capital Markets	Outperform	$19
Oct-13-21	Initiated	Oppenheimer	Outperform	$21

Show Previous Ratings

Sep-10-24 07:30AM	Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma (GlobeNewswire) +5.13%
Sep-04-24 04:30PM	Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-24 07:00AM	Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments (GlobeNewswire) +12.40%
Jun-19-24 08:00AM	Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors (GlobeNewswire)
Jun-17-24 04:30PM	Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit (GlobeNewswire)
08:00AM	Loading…
Jun-14-24 08:00AM	Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress (GlobeNewswire)
May-30-24 06:05PM	Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 (GlobeNewswire) +7.72%
May-29-24 04:30PM	Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 01:53PM	JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments (GlobeNewswire)
May-13-24 08:00AM	Jasper Therapeutics Announces Briquilimab Development Program in Asthma (GlobeNewswire)
May-07-24 04:30PM	Jasper Therapeutics to Present at Upcoming Investor Conferences in May (GlobeNewswire) -6.94%
12:00PM	Jasper Therapeutics (JSPR) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-02-24 04:30PM	Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.42%
Mar-22-24 08:50AM	Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
04:30PM	Loading…
Mar-21-24 04:30PM	Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire) +8.01%
Mar-19-24 08:00AM	Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria (GlobeNewswire) +5.55%
Mar-15-24 08:00AM	New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia (GlobeNewswire)
Mar-14-24 12:00PM	Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know (Zacks) -9.11%
Mar-06-24 12:53PM	JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +8.21%
08:50AM	Here's Why Momentum in Jasper Therapeutics, Inc. (JSPR) Should Keep going (Zacks)
Mar-04-24 07:30AM	Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Feb-26-24 04:30PM	Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference (GlobeNewswire)
Feb-23-24 08:00AM	Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting (GlobeNewswire)
Feb-19-24 08:50AM	Here's What Could Help Jasper Therapeutics, Inc. (JSPR) Maintain Its Recent Price Strength (Zacks)
Feb-07-24 08:00AM	Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference (GlobeNewswire) +18.00%
Feb-06-24 08:59AM	Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock (GlobeNewswire) +14.52%
Feb-05-24 08:00AM	Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting (GlobeNewswire) +7.65%
Feb-02-24 08:00AM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-24-24 12:14PM	Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why (Zacks)
08:30AM	Loading…
Jan-05-24 08:30AM	Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones (GlobeNewswire)
Jan-02-24 08:00AM	Jasper Therapeutics, Inc. Announces Reverse Stock Split (GlobeNewswire) -13.74%
Dec-18-23 04:30PM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +12.11%
Dec-10-23 11:00AM	Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023 (GlobeNewswire)
Nov-30-23 08:00AM	Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria (GlobeNewswire)
Nov-09-23 09:48AM	Jasper Therapeutics Inc (JSPR) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) -8.08%
08:00AM	Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-08-23 04:30PM	Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences (GlobeNewswire)
Nov-02-23 09:00AM	Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023 (GlobeNewswire)
Nov-01-23 08:00AM	Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors (GlobeNewswire)
Oct-09-23 08:30AM	Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023 (GlobeNewswire) +16.25%
08:00AM	Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria (GlobeNewswire)
Sep-25-23 08:00AM	Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer (GlobeNewswire) -8.97%
Sep-21-23 08:00AM	Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium (GlobeNewswire)
Sep-15-23 08:00AM	Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference (GlobeNewswire) +10.96%
Aug-11-23 04:05PM	Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-04-23 04:51PM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-02-23 08:00AM	Jasper Therapeutics Strengthens Management Team with Key Appointments (GlobeNewswire)
Jun-22-23 08:00AM	Jasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome (GlobeNewswire)
Jun-20-23 08:00AM	Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors (GlobeNewswire)
Jun-13-23 08:00AM	Jasper Therapeutics Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer (GlobeNewswire) +6.17%
May-12-23 04:05PM	Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) +5.37%
May-10-23 08:00AM	Jasper Therapeutics Announces Appointment of Stephen J. Galli, M.D. to Scientific Advisory Board (GlobeNewswire)
Apr-13-23 08:00AM	Jasper Therapeutics Announces Appointment of Matthew Ford as Vice President, Human Resources (GlobeNewswire)
Apr-10-23 04:05PM	Jasper Therapeutics Appoints David Hinds as Senior Vice President, Development Operations (GlobeNewswire)
Mar-31-23 08:00AM	Jasper Therapeutics to Present at Cantor Fitzgeralds The Future of Oncology Virtual Symposium (GlobeNewswire)
Mar-23-23 08:00AM	Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer (GlobeNewswire)
Mar-09-23 08:00AM	Jasper Therapeutics to Present at Upcoming Conferences (GlobeNewswire) -7.00%
Mar-08-23 04:05PM	Jasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-17-23 08:20AM	Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors (GlobeNewswire)
08:10AM	Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR (GlobeNewswire)
08:00AM	Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR (GlobeNewswire)
Feb-16-23 04:05PM	Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients (GlobeNewswire)
Feb-03-23 04:05PM	Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.43%
Jan-30-23 08:00AM	Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023 (GlobeNewswire)
Jan-27-23 01:10PM	Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jan-25-23 08:00AM	Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock (GlobeNewswire) +9.47%
Jan-24-23 04:25PM	Jasper Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) -5.59%
Jan-13-23 08:00AM	Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (GlobeNewswire) +7.88%
Jan-10-23 08:00AM	Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases (GlobeNewswire)
Jan-04-23 08:00AM	Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant (GlobeNewswire) -21.90%
Jan-03-23 08:00AM	Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia (GlobeNewswire) +467.41%
Nov-10-22 04:05PM	Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Sep-26-22 08:00AM	Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting (GlobeNewswire)
Sep-23-22 08:00AM	Jasper Therapeutics to Present at Upcoming Conferences (GlobeNewswire) -13.49%
Sep-15-22 08:00AM	Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with severe combined immunodeficiency (SCID) undergoing allogeneic hematopoietic stem cell transplant (GlobeNewswire)
Aug-12-22 04:05PM	Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire) -7.08%
Jun-23-22 04:05PM	Jasper Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium (GlobeNewswire) +17.34% +15.27%
Jun-20-22 10:59AM	Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-07-22 08:00AM	Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference (GlobeNewswire) -5.70%
Jun-06-22 08:00AM	Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022 (GlobeNewswire)
May-27-22 08:00AM	After a record-breaking decade, biotech is discovering what hard times feel like (American City Business Journals)
May-17-22 08:00AM	Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia (GlobeNewswire)
May-12-22 04:05PM	Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-28-22 08:00AM	Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting (GlobeNewswire)
Apr-26-22 04:05PM	Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation (GlobeNewswire)
Apr-22-22 08:00AM	Jasper Therapeutics to Host In-Person Key Opinion Leader Webinar on Transforming Hematopoietic Stem Cell Therapies (GlobeNewswire)
Mar-31-22 08:00AM	Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting (GlobeNewswire) +5.97%
Mar-25-22 07:30PM	Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-21-22 08:30AM	Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team (GlobeNewswire)
Mar-18-22 04:05PM	Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-10-22 08:00AM	Jasper Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire) -7.96%
Feb-28-22 08:00AM	Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer (GlobeNewswire)
Feb-24-22 05:19PM	Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-02-22 01:38PM	Grace Capital Buys Vanguard Consumer Discretionary ETF, Tesla Inc, Jasper Therapeutics Inc, ... (GuruFocus.com) -12.07%
Dec-08-21 11:15AM	Billionaire Ken Griffin Goes Big on These 3 Strong Buy Stocks (TipRanks) +6.00%
08:30AM	Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-20-21 08:21AM	Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth (Simply Wall St.)
Nov-12-21 04:05PM	Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-21 08:00AM	Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy (GlobeNewswire)

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mahal Jeetinder Singh	Chief Operating Officer	Sep 12 '24	Option Exercise	7.10	900	6,390	25,909	Sep 12 05:19 PM
Mahal Jeetinder Singh	Chief Operating Officer	Sep 12 '24	Sale	21.23	900	19,104	25,009	Sep 12 05:19 PM
Jeetinder Singh Mahal	Executive Officer	Sep 12 '24	Proposed Sale	20.66	900	18,590		Sep 12 05:18 PM
Mahal Jeetinder Singh	Chief Operating Officer	Jun 12 '24	Option Exercise	7.10	900	6,390	25,909	Jun 12 09:40 PM
Mahal Jeetinder Singh	Chief Operating Officer	Jun 12 '24	Sale	24.16	900	21,740	25,009	Jun 12 09:40 PM
Mahal Jeetinder Singh	Chief Operating Officer	Mar 12 '24	Option Exercise	7.10	900	6,390	25,909	Mar 12 09:33 PM
Mahal Jeetinder Singh	Chief Operating Officer	Mar 12 '24	Sale	26.44	900	23,792	25,009	Mar 12 09:33 PM
Carlyle Group Inc.	Former 10% Owner	Feb 08 '24	Buy	12.95	190,000	2,460,500	1,066,189	Feb 12 06:23 PM
Velan Capital Investment Manag	10% Owner	Feb 08 '24	Buy	12.95	350,000	4,532,500	1,188,500	Feb 09 08:40 PM
WIGGANS THOMAS G	Director	Nov 28 '23	Buy	0.65	10,000	6,486	50,000	Nov 30 04:05 PM
WIGGANS THOMAS G	Director	Nov 21 '23	Buy	0.64	10,000	6,383	40,000	Nov 22 04:06 PM
WIGGANS THOMAS G	Director	Nov 20 '23	Buy	0.63	10,000	6,309	30,000	Nov 20 08:14 PM
WIGGANS THOMAS G	Director	Nov 17 '23	Buy	0.60	10,000	5,966	20,000	Nov 20 08:14 PM
WIGGANS THOMAS G	Director	Nov 16 '23	Buy	0.60	10,000	5,965	10,000	Nov 20 08:14 PM
Lis William	Director	Oct 13 '23	Sale	0.85	7,965	6,777	53,521	Oct 13 06:56 PM

Open in Screener

MKSI

MKS Instruments, Inc.

Sep 20 • 04:00PM ET

109.88

Dollar change -4.22
Percentage change -3.70	%

Technology • Scientific & Technical Instruments • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IJH VB VBR SOXX VXF VGT SOXL MDY SCHA

Index	-	P/E	857.77	EPS (ttm)	0.13	Insider Own	0.55%	Shs Outstand	67.29M	Perf Week	-1.76%
Market Cap	7.39B	Forward P/E	14.65	EPS next Y	7.50	Insider Trans	-0.76%	Shs Float	66.92M	Perf Month	-9.21%
Income	9.00M	PEG	33.68	EPS next Q	1.45	Inst Own	101.29%	Short Float	4.44%	Perf Quarter	-16.38%
Sales	3.58B	P/S	2.07	EPS this Y	27.35%	Inst Trans	9.09%	Short Ratio	3.13	Perf Half Y	-13.82%
Book/sh	33.18	P/B	3.31	EPS next Y	32.93%	ROA	0.10%	Short Interest	2.97M	Perf Year	25.85%
Cash/sh	12.65	P/C	8.69	EPS next 5Y	25.46%	ROE	0.38%	52W Range	63.44 - 147.40	Perf YTD	6.81%
Dividend Est.	0.88 (0.80%)	P/FCF	18.91	EPS past 5Y	-	ROI	0.12%	52W High	-25.45%	Beta	1.63
Dividend TTM	0.88 (0.80%)	Quick Ratio	2.31	Sales past 5Y	12.63%	Gross Margin	39.30%	52W Low	73.20%	ATR (14)	5.21
Dividend Ex-Date	Aug 26, 2024	Current Ratio	3.58	EPS Y/Y TTM	100.50%	Oper. Margin	13.18%	RSI (14)	46.96	Volatility	3.72% 3.91%
Employees	10200	Debt/Eq	2.29	Sales Y/Y TTM	-6.67%	Profit Margin	0.25%	Recom	1.83	Target Price	138.64
Option/Short	Yes / Yes	LT Debt/Eq	2.25	EPS Q/Q	101.29%	Payout	-	Rel Volume	1.75	Prev Close	114.10
Sales Surprise	2.38%	EPS Surprise	46.17%	Sales Q/Q	-11.57%	Earnings	Aug 07 AMC	Avg Volume	949.68K	Price	109.88
SMA20	-1.88%	SMA50	-6.71%	SMA200	-7.07%	Trades		Volume	1,660,186	Change	-3.70%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-16-24	Downgrade	Citigroup	Buy → Neutral	$145 → $120
Sep-10-24	Initiated	Cantor Fitzgerald	Overweight	$140
Sep-03-24	Initiated	Goldman	Neutral	$129
Aug-05-24	Initiated	Morgan Stanley	Overweight	$155
Jul-10-24	Initiated	BofA Securities	Buy	$160
Jun-20-24	Resumed	Deutsche Bank	Hold	$140
Mar-01-23	Upgrade	The Benchmark Company	Hold → Buy	$125
Dec-20-22	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$100
Nov-04-22	Downgrade	The Benchmark Company	Buy → Hold
Feb-23-22	Initiated	Loop Capital	Buy	$200
Jan-26-22	Initiated	KeyBanc Capital Markets	Sector Weight
Dec-27-21	Reiterated	Needham	Buy	$215
Dec-13-21	Upgrade	Citigroup	Neutral → Buy	$190
Oct-29-21	Resumed	Rosenblatt	Buy
Aug-20-21	Resumed	Citigroup	Neutral	$160
Jul-06-21	Resumed	Deutsche Bank	Buy	$225
Dec-11-20	Reiterated	Cowen	Outperform	$150 → $178
Sep-11-20	Initiated	Berenberg	Buy
Jul-28-20	Reiterated	Needham	Buy	$125 → $135
Jul-22-20	Initiated	Rosenblatt	Buy	$162

Show Previous Ratings

Sep-10-24 09:00AM	MKS Instruments CEO to be Honored as Pinnacle Award Winner by the Asian American Business Development Center (GlobeNewswire)
Sep-09-24 09:40AM	Here's Why MKS Instruments (MKSI) is a Strong Value Stock (Zacks)
Sep-06-24 11:31AM	Why Is MKS Instruments (MKSI) Down 1.3% Since Last Earnings Report? (Zacks)
Sep-04-24 09:50AM	Why MKS Instruments (MKSI) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-21-24 09:00AM	MKS Instruments to Participate in Citi's 2024 Global TMT Conference (GlobeNewswire)
09:00AM	Loading…
Aug-13-24 09:00AM	Ram Mayampurath to Join MKS Instruments as Chief Financial Officer (GlobeNewswire) +5.31%
Aug-08-24 11:51PM	Q2 2024 MKS Instruments Inc Earnings Call (Thomson Reuters StreetEvents) +6.23%
08:49AM	MKS Instruments (MKSI) Q2 Earnings Top Estimates, Revenues Down (Zacks)
Aug-07-24 07:50PM	MKS Instruments (MKSI) Q2 Earnings and Revenues Surpass Estimates (Zacks)
06:55PM	MKS Instruments: Q2 Earnings Snapshot (Associated Press Finance)
04:30PM	MKS Instruments Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-06-24 09:40AM	Why MKS Instruments (MKSI) is a Top Value Stock for the Long-Term (Zacks)
09:00AM	MKS Instruments Declares Quarterly Cash Dividend (GlobeNewswire)
Aug-05-24 09:45AM	Here's Why MKS Instruments (MKSI) is a Strong Growth Stock (Zacks)
Aug-01-24 01:37PM	MKS Instruments (MKSI) Surges 5.6%: Is This an Indication of Further Gains? (Zacks) -8.86%
12:45PM	Loading…
12:45PM	Here is Why Growth Investors Should Buy MKS Instruments (MKSI) Now (Zacks)
Jul-31-24 10:01AM	MKS Instruments (MKSI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks) +5.57%
Jul-29-24 09:00AM	MKS Instruments Releases 2024 Environmental, Social, Governance Report (GlobeNewswire)
Jul-23-24 12:10PM	Will MKS Instruments (MKSI) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:00AM	MKS Instruments Completes Repricing and Makes a $110 Million Voluntary Prepayment on its Secured Term Loan B (GlobeNewswire)
Jul-19-24 09:45AM	Why MKS Instruments (MKSI) is a Top Growth Stock for the Long-Term (Zacks)
Jul-16-24 12:45PM	Looking for a Growth Stock? 3 Reasons Why MKS Instruments (MKSI) is a Solid Choice (Zacks)
12:00PM	Are You Looking for a Top Momentum Pick? Why MKS Instruments (MKSI) is a Great Choice (Zacks)
Jul-15-24 08:00AM	MKS Instruments Announces Second Quarter 2024 Earnings Conference Call (GlobeNewswire)
Jun-19-24 09:50AM	Why MKS Instruments (MKSI) is a Top Momentum Stock for the Long-Term (Zacks)
Jun-18-24 09:00AM	MKS Instruments Named in U.S. News & World Report's 2024-2025 Best Companies to Work For (GlobeNewswire)
Jun-14-24 02:18AM	MKS Instruments expands to Malaysia with new Penang plant, supporting chip production (DigiTimes)
Jun-10-24 09:00AM	MKS Instruments Set to Build a Super Center Factory in Malaysia (GlobeNewswire)
Jun-07-24 11:30AM	MKS Instruments (MKSI) Up 1.4% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-06-24 03:11PM	AI Needs More Chip Factories. These Stocks Should Benefit. (Barrons.com)
08:00AM	Loading…
May-23-24 08:00AM	MKS Instruments to Participate in BofA Securities Global Technology Conference (GlobeNewswire)
May-16-24 04:57PM	MKS Instruments Closes $1.4 Billion Debt Offering (MT Newswires)
04:15PM	MKS Instruments Announces Closing of Private Offering of $1.4 Billion of 1.25% Convertible Senior Notes, Including Full Exercise of Option to Purchase $200 Million of Additional Notes (GlobeNewswire)
May-14-24 09:00AM	Sector Update: Tech Stocks Mixed Premarket Tuesday (MT Newswires)
04:59AM	MKS Instruments Prices Upsized $1.2 Billion Private Senior Notes Offering (MT Newswires)
May-13-24 11:01PM	MKS Instruments Announces Pricing of Upsized Private Offering of $1.2 Billion of 1.25% Convertible Senior Notes (GlobeNewswire) -9.03%
02:25PM	Tap Into Trends: 3 Thematic ETFs to Capture the Market's Pulse (InvestorPlace)
09:49AM	MKS Instruments Plans to Offer $1 Billion in Private Placement of Convertible Senior Notes Due 2030 (MT Newswires)
06:37AM	MKS Instruments Announces Proposed Private Offering of $1.0 Billion of Convertible Senior Notes (GlobeNewswire)
May-10-24 12:30PM	MKS Instruments Inc (MKSI) Exceeds Q1 Earnings Expectations, Surpassing Analyst Forecasts (GuruFocus.com)
10:35AM	MKS Instruments, Inc. (NASDAQ:MKSI) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 10:40PM	Q1 2024 MKS Instruments Inc Earnings Call (Thomson Reuters StreetEvents)
10:59AM	MKS Instruments (MKSI) Q1 Earnings Top Estimates, Revenues Up (Zacks)
May-08-24 06:15PM	MKS Instruments (MKSI) Q1 Earnings and Revenues Beat Estimates (Zacks)
05:32PM	MKS Instruments Q1 Non-GAAP Earnings, Revenue Increase; Q2 Guidance Set -- Shares Rise After Hours (MT Newswires)
05:14PM	MKS Instruments: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	MKS Instruments Reports First Quarter 2024 Financial Results (GlobeNewswire)
09:00AM	MKS Instruments Declares Quarterly Cash Dividend (GlobeNewswire)
May-06-24 09:00AM	MKS Receives Samsung Electro-Mechanics (SEMCO) Supplier Excellence Award to Demonstrate Global Competitiveness (GlobeNewswire)
May-04-24 07:38AM	23 Most Profitable Stocks of the Last 12 Months (Insider Monkey)
Apr-15-24 08:00AM	MKS Instruments Announces First Quarter 2024 Earnings Conference Call (GlobeNewswire)
Mar-08-24 11:30AM	Why Is MKS Instruments (MKSI) Up 16.9% Since Last Earnings Report? (Zacks)
Mar-04-24 01:00PM	Insider Sell: EVP, GC & Secretary Kathleen Burke Sells 7,411 Shares of MKS Instruments Inc ... (GuruFocus.com)
Feb-29-24 01:57AM	16 Best Future Stocks For The Long Term (Insider Monkey)
Feb-28-24 04:00PM	MKS Instruments Receives 2023 Outstanding Service Award from MFLEX (GlobeNewswire)
Feb-26-24 01:00PM	EVP, CFO & Treasurer Seth Bagshaw Sells 32,865 Shares of MKS Instruments Inc (GuruFocus.com)
Feb-09-24 09:01AM	MKS Instruments, Inc. (NASDAQ:MKSI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-08-24 09:57PM	Q4 2023 MKS Instruments Inc Earnings Call (Thomson Reuters StreetEvents) +5.62%
10:30AM	MKS Instruments (MKSI) Q4 Earnings Top Estimates, Revenues Up (Zacks)
Feb-07-24 05:12PM	MKS Instruments: Q4 Earnings Snapshot (Associated Press Finance)
04:57PM	MKS Instruments Inc (MKSI) Exceeds Q4 Revenue Expectations Despite Net Loss (GuruFocus.com)
04:30PM	MKS Instruments Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-06-24 09:00AM	MKS Instruments Declares Quarterly Cash Dividend (GlobeNewswire)
Jan-30-24 09:00AM	MKS Instruments Recognized by TSMC for Outstanding Production Support (GlobeNewswire)
Jan-25-24 09:00AM	MKS Instruments Selected as a 2024 Campus Forward Award Winner by RippleMatch (GlobeNewswire)
Jan-24-24 04:30PM	MKS Instruments Showcases Customer-Focused Photonics Innovations at SPIE's Photonics West 2024 (GlobeNewswire)
Jan-23-24 08:00AM	MKS Instruments Announces Fourth Quarter and Full Year 2023 Earnings Conference Call (GlobeNewswire)
Jan-22-24 04:10PM	MKS Instruments Completes Refinancing of Secured Term Loan A (GlobeNewswire)
Jan-08-24 09:00AM	MKS Instruments to Participate in Needham's 26th Annual Growth Conference (GlobeNewswire)
Dec-20-23 09:00AM	MKS Instruments Commits to Reduce Carbon Emissions (GlobeNewswire)
Dec-07-23 09:00AM	MKS Instruments Named One of America's Most Responsible Companies (GlobeNewswire)
Dec-04-23 07:00AM	Seth H. Bagshaw to Retire as Chief Financial Officer of MKS Instruments (GlobeNewswire)
Dec-01-23 11:31AM	Why Is MKS Instruments (MKSI) Up 24.8% Since Last Earnings Report? (Zacks)
05:40AM	Got $2,000? Here Are 2 Beaten-Down Growth Stocks to Buy Right Now (Motley Fool)
Nov-23-23 05:08AM	MKS Instruments Inc's Dividend Analysis (GuruFocus.com)
Nov-07-23 09:00AM	MKS Instruments Declares Quarterly Cash Dividend (GlobeNewswire)
Nov-03-23 03:32PM	MKS Instruments, Inc. (NASDAQ:MKSI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-01-23 06:17PM	MKS Instruments: Q3 Earnings Snapshot (Associated Press Finance)
04:30PM	MKS Instruments Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-20-23 09:00AM	MKS Instruments Announces Third Quarter 2023 Earnings Conference Call (GlobeNewswire)
Oct-18-23 05:49AM	Should You Hold MKS Instruments (MKSI)? (Insider Monkey)
Oct-10-23 09:00AM	MKS Instruments Releases Third Annual Environmental, Social, Governance Report (GlobeNewswire)
Oct-06-23 12:00PM	MKS Instruments (MKSI) Upgraded to Buy: Here's Why (Zacks)
Oct-03-23 04:30PM	MKS Instruments Completes Repricing of Secured Term Loan B (GlobeNewswire)
Sep-28-23 09:00AM	MKS Instruments Recognized as a 2024 Best Company to Work For (GlobeNewswire)
Sep-08-23 08:58AM	Zacks Industry Outlook Highlights Axcelis, MKS Instruments and Kulicke and Soffa Industries (Zacks)
Sep-07-23 12:18PM	3 Electronics Stocks to Watch From a Prospering Industry (Zacks)
Sep-01-23 11:31AM	Why Is MKS Instruments (MKSI) Down 1.2% Since Last Earnings Report? (Zacks)
Aug-28-23 09:00AM	MKS Instruments to Participate in Citis 2023 Global Technology Conference (GlobeNewswire)
Aug-13-23 09:14AM	Further weakness as MKS Instruments (NASDAQ:MKSI) drops 6.2% this week, taking three-year losses to 23% (Simply Wall St.)
Aug-08-23 09:00AM	MKS Instruments Declares Quarterly Cash Dividend (GlobeNewswire)
Aug-03-23 10:26PM	Q2 2023 MKS Instruments Inc Earnings Call (Thomson Reuters StreetEvents)
11:26AM	MKS Instruments (MKSI) Q2 Earnings Top Estimates, Revenues Up (Zacks)
Aug-02-23 07:35PM	MKS Instruments (MKSI) Beats Q2 Earnings and Revenue Estimates (Zacks)
06:32PM	MKS Instruments: Q2 Earnings Snapshot (AP Finance)
04:30PM	MKS Instruments Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-21-23 09:00AM	MKS Instruments Announces Second Quarter 2023 Earnings Conference Call (GlobeNewswire)
Jul-18-23 09:00AM	MKS Instruments Announces Second Quarter 2023 Earnings Conference Call (GlobeNewswire)
Jul-13-23 02:56PM	Chuck Royce Portfolio, Performance and Net Worth (Insider Monkey)
Jun-21-23 08:00PM	MKSI: Lowering target price to $108.00 (Argus Research)

MKS Instruments, Inc. provides instruments, systems, subsystems and process control solutions to measure, control, power, monitor, and analyze parameters of manufacturing processes to improve process performance and productivity for its customers. It operates through the following segments: Vacuum & Analysis, Light & Motion and Equipment & Solutions. The Vacuum & Analysis segment comprises pressure measurement and control, flow measurement and control, gas and vapor delivery, gas composition analysis, residual gas analysis, leak detection, control technology, ozone generation and delivery, RF & DC power, reactive gas generation and vacuum technology components. The Light & Motion segment includes lasers, photonics, sub-micron positioning, vibration control, and optics instruments. The Equipment & Solutions segment provides laser-based manufacturing systems solutions for the micro-machining industry that enable customers to optimize production. The company was founded in 1961 and is headquartered in Andover, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mora Elizabeth	Director	Sep 03 '24	Sale	115.97	275	31,892	17,934	Sep 04 01:28 PM
Mora Elizabeth	Director	Sep 03 '24	Proposed Sale	115.97	275	31,892		Sep 03 09:47 AM
Williams John Edward	EVP & GM, PSD	Aug 16 '24	Sale	118.71	1,800	213,678	13	Aug 19 11:59 AM
Williams John Edward	Officer	Aug 16 '24	Proposed Sale	118.71	1,800	213,678		Aug 16 01:00 PM
Moloney Jacqueline F	Director	Aug 01 '24	Sale	123.46	250	30,865	10,533	Aug 02 12:13 PM
Moloney Jacqueline F	Director	Aug 01 '24	Proposed Sale	123.46	250	30,865		Aug 01 02:56 PM
Mora Elizabeth	Director	Jun 03 '24	Sale	129.41	275	35,588	18,209	Jun 04 01:45 PM
Mora Elizabeth	Director	Apr 01 '24	Sale	133.00	250	33,250	16,862	Apr 02 11:36 AM
Moloney Jacqueline F	Director	Mar 01 '24	Sale	122.89	250	30,722	9,161	Mar 04 11:43 AM
Burke Kathleen Flaherty	EVP, GC & Secretary	Mar 01 '24	Sale	122.89	7,411	910,738	42,999	Mar 04 11:39 AM
BAGSHAW SETH H	EVP, CFO & Treasurer	Feb 22 '24	Sale	123.28	32,865	4,051,629	1	Feb 26 11:51 AM
Moloney Jacqueline F	Director	Feb 16 '24	Sale	124.10	1,917	237,933	9,411	Feb 20 03:21 PM
COLELLA GERARD G	Director	Feb 09 '24	Sale	120.00	10,000	1,200,003	68,017	Feb 12 12:21 PM
COLELLA GERARD G	Director	Jan 22 '24	Sale	110.00	10,000	1,100,004	78,017	Jan 23 01:45 PM
Mora Elizabeth	Director	Jan 02 '24	Sale	100.90	250	25,225	17,112	Jan 03 01:54 PM
Moloney Jacqueline F	Director	Dec 01 '23	Sale	82.23	250	20,558	11,328	Dec 04 10:17 AM
Henry David Philip	EVP, Operations & Corp Mktg	Nov 07 '23	Buy	68.34	2,500	170,862	11,073	Nov 08 11:40 AM
Mora Elizabeth	Director	Oct 02 '23	Sale	87.15	250	21,788	17,362	Oct 03 02:34 PM

Open in Screener

VERA

Vera Therapeutics Inc

Sep 20 • 04:00PM ET

42.78

Dollar change +0.79
Percentage change 1.88	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: XBI VTI IWM VXF IWO IBB SCHA VTWO VHT LABU

Index	RUT	P/E	-	EPS (ttm)	-2.20	Insider Own	24.24%	Shs Outstand	44.45M	Perf Week	14.05%
Market Cap	2.35B	Forward P/E	-	EPS next Y	-2.79	Insider Trans	-7.53%	Shs Float	41.54M	Perf Month	7.11%
Income	-107.85M	PEG	-	EPS next Q	-0.66	Inst Own	90.09%	Short Float	14.56%	Perf Quarter	19.20%
Sales	0.00M	P/S	-	EPS this Y	-13.08%	Inst Trans	1.75%	Short Ratio	11.11	Perf Half Y	-0.21%
Book/sh	5.98	P/B	7.15	EPS next Y	-9.68%	ROA	-36.41%	Short Interest	6.05M	Perf Year	161.01%
Cash/sh	7.01	P/C	6.10	EPS next 5Y	-	ROE	-46.05%	52W Range	9.24 - 50.78	Perf YTD	178.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.22%	ROI	-28.49%	52W High	-15.75%	Beta	0.99
Dividend TTM	-	Quick Ratio	21.15	Sales past 5Y	0.00%	Gross Margin	-	52W Low	362.99%	ATR (14)	2.17
Dividend Ex-Date	-	Current Ratio	21.15	EPS Y/Y TTM	33.79%	Oper. Margin	0.00%	RSI (14)	67.58	Volatility	6.66% 5.34%
Employees	51	Debt/Eq	0.16	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.22	Target Price	61.33
Option/Short	Yes / Yes	LT Debt/Eq	0.15	EPS Q/Q	-35.24%	Payout	-	Rel Volume	2.42	Prev Close	41.99
Sales Surprise	-	EPS Surprise	-10.71%	Sales Q/Q	-	Earnings	Aug 08 BMO	Avg Volume	544.09K	Price	42.78
SMA20	11.52%	SMA50	14.56%	SMA200	20.99%	Trades		Volume	1,316,398	Change	1.88%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-25-24	Initiated	Oppenheimer	Outperform	$26
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight
Dec-18-23	Initiated	Raymond James	Outperform	$29
Nov-10-23	Upgrade	Jefferies	Hold → Buy	$18 → $26
Aug-16-23	Initiated	Guggenheim	Buy	$27
Jan-04-23	Downgrade	Wedbush	Outperform → Neutral	$33 → $8
Jan-04-23	Downgrade	Jefferies	Buy → Hold	$32 → $6
Jul-12-22	Initiated	JP Morgan	Overweight	$35
May-02-22	Initiated	H.C. Wainwright	Buy	$35
Apr-19-22	Initiated	Wedbush	Outperform	$32

Sep-16-24 08:00AM	Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024 (GlobeNewswire) +6.90%
Sep-12-24 08:00AM	Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN (GlobeNewswire) -5.08%
Sep-10-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 01:07AM	Vera Therapeutics, Inc. (VERA): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-03-24 08:27AM	Adobe Stock Added to JP Morgan Focus List. Heres Why. (Barrons.com)
08:27AM	Loading…
08:27AM	Adobe and 2 More Stocks Added to JP Morgan Focus List. Heres Why. (Barrons.com)
07:49AM	Load Up on Adobe and These 2 Stocks This September, J.P. Morgan Says (Barrons.com)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 08:00AM	Vera Therapeutics to Participate at September Investor Conferences (GlobeNewswire)
Aug-09-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 08:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-05-24 04:30PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-24 08:00AM	Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer (GlobeNewswire)
Jun-11-24 04:01PM	Vera Therapeutics Appoints Christy J. Oliger to Board of Directors (GlobeNewswire)
Jun-07-24 04:05PM	Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
04:05PM	Loading…
04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-24 08:00AM	Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN) (GlobeNewswire)
May-25-24 09:40AM	Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress (GlobeNewswire)
May-17-24 04:27PM	Vera Therapeutics Insider Sold Shares Worth $1,304,435, According to a Recent SEC Filing (MT Newswires)
May-10-24 05:38AM	Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating (MT Newswires)
May-09-24 01:53PM	VERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024 (InvestorPlace) -5.81%
08:00AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 04:38PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-23-24 05:09PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Apr-13-24 05:29AM	Could This Stock Be the Next Biotech Buyout? (Motley Fool)
Apr-12-24 07:01PM	Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ... (GuruFocus.com)
Apr-11-24 04:29PM	Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal (Yahoo Finance Video) +17.30%
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-02-24 08:00AM	Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress (GlobeNewswire)
Mar-20-24 12:52PM	VERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:30AM	Loading…
07:30AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-28-24 04:20PM	Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-02-24 12:40PM	Hedge Fund and Insider Trading News: Anthony Scaramucci, Ray Dalio, Ken Griffin, NWQ Capital Management, Man Group, Cleveland-Cliffs Inc (CLF), Vera Therapeutics, Inc. (VERA), and More (Insider Monkey)
08:00AM	Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Feb-01-24 04:05PM	Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Class A Common Stock (GlobeNewswire)
Jan-29-24 11:50PM	Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock (GlobeNewswire) +11.46%
06:15AM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
Jan-25-24 06:30AM	Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy (GlobeNewswire) +48.71%
Jan-12-24 06:44PM	Why Vera Therapeutics Stock Soared by 22% This Week (Motley Fool) -11.35%
Jan-08-24 08:01AM	Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer (GlobeNewswire) +16.74%
08:00AM	Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024 (GlobeNewswire)
Dec-27-23 08:00AM	Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-23 10:15AM	This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street (Motley Fool) +8.70%
Nov-14-23 05:05PM	FMR LLC Adjusts Stake in Vera Therapeutics Inc (GuruFocus.com) +6.74%
09:55AM	Wall Street Analysts Believe Vera Therapeutics, Inc. (VERA) Could Rally 86.76%: Here's is How to Trade (Zacks)
Nov-09-23 09:29AM	Vera Therapeutics Inc (VERA) Reports Q3 Financial Results and Business Updates (GuruFocus.com)
08:00AM	Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results (GlobeNewswire)
Nov-04-23 10:00AM	Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023 (GlobeNewswire)
Oct-30-23 08:00AM	Vera Therapeutics Scheduled to Present at November Investor Conferences (GlobeNewswire) +8.32%
Oct-18-23 09:35AM	Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA) (Zacks) -5.09%
Oct-17-23 09:35AM	Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA) (Zacks)
Oct-16-23 09:35AM	Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a Turnaround (Zacks)
Oct-13-23 10:22AM	Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting (GlobeNewswire)
Sep-26-23 04:02PM	Why Shares of Vera Therapeutics Jumped Tuesday (Motley Fool) +11.32%
Aug-31-23 08:00AM	Vera Therapeutics Scheduled to Present at September Investor Conferences (GlobeNewswire) -5.70%
Aug-16-23 10:00AM	Chevron upgraded, SolarEdge downgraded: Wall Street's top analyst calls (The Fly)
Aug-15-23 04:03PM	What Makes Vera Therapeutics, Inc. (VERA) a New Buy Stock (Zacks)
Aug-10-23 08:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results (GlobeNewswire) +6.22%
Aug-04-23 06:30PM	Apogee Therapeutics, Turnstone Biologics, and More Stocks See Action From Activist Investors (Barrons.com)
Jul-24-23 09:01AM	Positive Signs As Multiple Insiders Buy Vera Therapeutics Stock (Simply Wall St.) -6.82%
Jul-07-23 06:35PM	Masimo and Vera Therapeutics Stock See Action From Activist Investors (Barrons.com) +5.20%
Jun-27-23 08:05AM	Vera Therapeutics Likely Needs Time to Digest Its Recent Dramatic Gains (TheStreet.com)
Jun-20-23 07:04PM	Why Shares of Vera Therapeutics Jumped Tuesday (Motley Fool) +16.94%
09:33AM	2 Surging Healthcare Stocks With More Fuel in the Tank (Motley Fool)
Jun-17-23 10:10AM	Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress (GlobeNewswire)
Jun-15-23 04:44PM	Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN (GlobeNewswire)
Jun-12-23 12:05PM	Why Shares of Vera Therapeutics Are Soaring Monday (Motley Fool) +15.83%
Jun-11-23 01:08PM	7 Stocks That Wall Street Analysts Are Loving in June (InvestorPlace)
Jun-08-23 08:00AM	Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
Jun-07-23 08:00AM	Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN) (GlobeNewswire)
May-11-23 08:36AM	Should You Buy Vera Therapeutics (VERA) Ahead of Earnings? (Zacks)
07:30AM	Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results (GlobeNewswire)
May-04-23 08:00AM	Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs (GlobeNewswire)
Mar-28-23 07:30AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 04:05PM	Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-14-23 07:48AM	Chief Financial Officer Sean Grant Just Bought 207% More Shares In Vera Therapeutics, Inc. (NASDAQ:VERA) (Simply Wall St.)
Feb-09-23 06:51AM	Daily Vickers Top Buyers & Sellers for 02/09/2023 (Argus Research)
05:54AM	With 35% stake, Vera Therapeutics, Inc. (NASDAQ:VERA) seems to have captured institutional investors' interest (Simply Wall St.)
Feb-06-23 04:05PM	Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Class A Common Stock (GlobeNewswire)
Feb-01-23 09:52PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire) -15.72%
04:01PM	Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock (GlobeNewswire)
Jan-30-23 07:35AM	Vera Therapeutics Releases Interim Analysis Of Rare Kidney Disease Drug, Deprioritizes Certain Phase 3 Programs (Benzinga) -6.06%
06:00AM	Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria (GlobeNewswire)
Jan-25-23 08:00AM	Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN) (GlobeNewswire)
Jan-22-23 07:39AM	Why Vera Therapeutics Stock Bolted Higher This Week (Motley Fool)
Jan-06-23 05:02AM	The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax (Zacks)
Jan-04-23 04:07PM	Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update And Chinook Popped (Investor's Business Daily) -64.70% -13.31%
12:20PM	VERA Dips Despite Positive Data From IgA Nephropathy Study (Zacks)
10:22AM	These 2 Nasdaq Biotechs Are Making Big Moves Wednesday (Motley Fool)
06:52AM	Vera Therapeutics Shares Plunge After Mixed Data From Rare Kidney Disease Study (Benzinga)
Jan-03-23 04:01PM	Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (GlobeNewswire) -5.43%
Dec-20-22 04:05PM	Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +5.44%
Nov-25-22 07:38AM	One Vera Therapeutics, Inc. (NASDAQ:VERA) insider upped their stake by 329% in the previous year (Simply Wall St.)
Nov-22-22 07:30AM	Vera Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-17-22 07:30AM	Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP (GlobeNewswire)
Nov-09-22 07:30AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire) -6.00%
Nov-05-22 04:50PM	Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney Week 2022 Annual Meeting (GlobeNewswire)
Oct-17-22 07:30AM	Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2022 Annual Meeting (GlobeNewswire)
Sep-15-22 09:55AM	Wall Street Analysts Think Vera Therapeutics, Inc. (VERA) Could Surge 64%: Read This Before Placing a Bet (Zacks)
Sep-07-22 07:30AM	Vera Therapeutics to Present at Upcoming Conferences in September 2022 (GlobeNewswire) +5.93%

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SEIDENBERG BETH C	Director	Sep 19 '24	Sale	42.31	13,823	584,793	146,553	Sep 20 04:45 PM
SEIDENBERG BETH C	Director	Sep 18 '24	Sale	42.00	1,476	61,992	4,012	Sep 20 04:45 PM
SEIDENBERG BETH C	Director	Sep 18 '24	Sale	42.01	1,177	49,448	160,376	Sep 20 04:45 PM
BETH C SEIDENBERG	Director	Sep 18 '24	Proposed Sale	40.02	15,000	600,300		Sep 18 04:38 PM
SAMUEL B SEIDENBERG IRREV TRUS	Director	Sep 18 '24	Proposed Sale	40.02	1,476	59,070		Sep 18 04:38 PM
Fordyce Marshall	PRESIDENT AND CEO	Sep 11 '24	Option Exercise	2.90	15,625	45,262	317,246	Sep 13 04:36 PM
Fordyce Marshall	PRESIDENT AND CEO	Sep 11 '24	Sale	37.50	15,625	585,934	307,972	Sep 13 04:36 PM
MARSHALL FORDYCE	Director	Sep 11 '24	Proposed Sale	37.55	31,250	1,173,438		Sep 11 04:19 PM
Fordyce Marshall	PRESIDENT AND CEO	Aug 28 '24	Option Exercise	2.90	15,625	45,262	337,592	Aug 30 04:04 PM
Fordyce Marshall	PRESIDENT AND CEO	Aug 28 '24	Sale	36.84	30,320	1,117,140	307,972	Aug 30 04:04 PM
MARSHALL FORDYCE	Director	Aug 28 '24	Proposed Sale	37.65	30,320	1,141,548		Aug 28 04:15 PM
Fordyce Marshall	PRESIDENT AND CEO	Aug 21 '24	Sale	39.76	14,471	575,425	322,667	Aug 23 05:40 PM
Fordyce Marshall	PRESIDENT AND CEO	Aug 14 '24	Option Exercise	2.90	15,625	45,262	352,763	Aug 16 04:31 PM
Fordyce Marshall	PRESIDENT AND CEO	Aug 14 '24	Sale	37.56	15,625	586,927	337,138	Aug 16 04:31 PM
MARSHALL FORDYCE	Director	Aug 14 '24	Proposed Sale	37.95	15,625	592,969		Aug 14 04:24 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	May 16 '24	Option Exercise	7.87	20,651	162,523	69,357	May 17 04:21 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	May 15 '24	Option Exercise	3.94	8,221	32,387	61,392	May 17 04:21 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	May 16 '24	Sale	42.32	20,651	873,890	51,206	May 17 04:21 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	May 15 '24	Sale	42.27	10,186	430,546	51,206	May 17 04:21 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Apr 10 '24	Sale	40.00	5,714	228,560	53,171	Apr 12 04:02 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Apr 03 '24	Option Exercise	14.87	99,828	1,484,442	166,165	Apr 05 09:32 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Apr 03 '24	Sale	39.61	99,828	3,954,516	66,337	Apr 05 09:32 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Apr 03 '24	Sale	39.42	18,649	735,205	0	Apr 05 09:32 PM
Katabi Maha	Director	Mar 22 '24	Sale	40.51	413,450	16,748,860	3,133,987	Mar 25 09:46 PM
Katabi Maha	Director	Mar 25 '24	Sale	40.50	340,000	13,770,000	2,793,987	Mar 25 09:46 PM
Katabi Maha	Director	Mar 21 '24	Sale	44.20	81,009	3,580,723	3,547,437	Mar 25 09:46 PM
Katabi Maha	Director	Jan 30 '24	Buy	31.00	161,290	4,999,990	3,628,446	Feb 01 05:58 PM
COMMODORE CAPITAL LP	10% Owner	Jan 10 '24	Sale	18.00	1,050,000	18,900,000	4,400,000	Jan 12 09:55 PM
Fordyce Marshall	President and CEO	Dec 29 '23	Option Exercise	2.87	13,516	38,854	256,877	Jan 03 04:15 PM

Open in Screener

ZI

ZoomInfo Technologies Inc.

Sep 20 • 04:00PM ET

10.29

Dollar change -0.35
Percentage change -3.29	%

Technology • Software - Application • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IJH COWZ VB VBK VXF MDY FDN SPMD IJJ

Index	-	P/E	286.63	EPS (ttm)	0.04	Insider Own	21.03%	Shs Outstand	384.83M	Perf Week	-3.11%
Market Cap	3.76B	Forward P/E	10.67	EPS next Y	0.96	Insider Trans	1.95%	Shs Float	288.46M	Perf Month	6.19%
Income	15.40M	PEG	43.83	EPS next Q	0.22	Inst Own	78.54%	Short Float	9.41%	Perf Quarter	-16.27%
Sales	1.23B	P/S	3.05	EPS this Y	-13.11%	Inst Trans	-3.93%	Short Ratio	3.60	Perf Half Y	-35.77%
Book/sh	5.08	P/B	2.03	EPS next Y	9.90%	ROA	0.22%	Short Interest	27.15M	Perf Year	-35.53%
Cash/sh	1.09	P/C	9.41	EPS next 5Y	6.54%	ROE	0.73%	52W Range	7.65 - 19.39	Perf YTD	-44.35%
Dividend Est.	-	P/FCF	9.14	EPS past 5Y	-	ROI	0.47%	52W High	-46.93%	Beta	1.05
Dividend TTM	-	Quick Ratio	0.97	Sales past 5Y	56.47%	Gross Margin	83.74%	52W Low	34.51%	ATR (14)	0.42
Dividend Ex-Date	-	Current Ratio	0.97	EPS Y/Y TTM	-88.28%	Oper. Margin	13.18%	RSI (14)	52.94	Volatility	3.64% 3.54%
Employees	3516	Debt/Eq	0.76	Sales Y/Y TTM	2.77%	Profit Margin	1.25%	Recom	2.64	Target Price	11.08
Option/Short	Yes / Yes	LT Debt/Eq	0.75	EPS Q/Q	-169.30%	Payout	0.00%	Rel Volume	1.81	Prev Close	10.64
Sales Surprise	-5.00%	EPS Surprise	-28.09%	Sales Q/Q	-5.54%	Earnings	Aug 05 AMC	Avg Volume	7.53M	Price	10.29
SMA20	3.15%	SMA50	0.32%	SMA200	-26.54%	Trades		Volume	13,601,733	Change	-3.29%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-24	Downgrade	Daiwa Securities	Outperform → Neutral	$15 → $9
Aug-06-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-06-24	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Aug-06-24	Downgrade	DA Davidson	Buy → Neutral	$20 → $9.50
Aug-06-24	Downgrade	BofA Securities	Buy → Underperform	$23 → $8
May-08-24	Downgrade	Piper Sandler	Overweight → Neutral	$24 → $15
May-08-24	Downgrade	Mizuho	Buy → Neutral	$23 → $14
May-08-24	Downgrade	Goldman	Neutral → Sell	$19.50 → $12
Mar-21-24	Initiated	KeyBanc Capital Markets	Overweight	$20
Feb-08-24	Downgrade	Citigroup	Neutral → Sell	$20 → $13
Feb-07-24	Initiated	Jefferies	Buy	$20
Feb-01-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$24 → $20
Jan-29-24	Upgrade	BofA Securities	Neutral → Buy	$20 → $25
Jan-12-24	Downgrade	Barclays	Overweight → Equal Weight	$18
Jan-08-24	Downgrade	RBC Capital Mkts	Sector Perform → Underperform	$16 → $14
Nov-01-23	Downgrade	Goldman	Buy → Neutral	$30 → $17
Sep-05-23	Initiated	Citigroup	Neutral	$19
Aug-02-23	Downgrade	Wolfe Research	Outperform → Peer Perform
Aug-01-23	Downgrade	Deutsche Bank	Buy → Hold	$20
Jul-24-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$30 → $28

Show Previous Ratings

Today 05:00PM	AI-Driven ZoomInfo Copilot Helps Sellers Capture Nearly 25% More Pipeline (Business Wire)
05:09AM	ZoomInfo Technologies (ZI) Faces Investor Backlash After Another Disappointing Earnings Report - Hagens Berman (Newsfile)
Sep-19-24 12:56PM	ZoomInfo Technologies (ZI) Faces Investor Backlash After Another Disappointing Earnings Report - Hagens Berman (GlobeNewswire)
Sep-18-24 09:40AM	ZoomInfo Copilot Summer Release Delivers Cutting-Edge AI Enhancements for Sellers (Business Wire)
Sep-17-24 12:08PM	ZoomInfo Technologies (ZI) Faces Investor Backlash After Another Disappointing Earnings Report - Hagens Berman (Newsfile)
02:40AM	Loading…
02:40AM	ZoomInfo Technologies Inc. (NASDAQ:ZI): A Non-Tech Stock With Long-Term Investment Potential (Insider Monkey)
Sep-16-24 05:37PM	ZoomInfo Technologies (ZI) Faces Investor Backlash After Another Disappointing Earnings Report - Hagens Berman (GlobeNewswire)
Sep-14-24 03:16PM	Zoominfo Technologies Inc. (ZI): Best Tech Stock To Buy Right Now Under $10? (Insider Monkey)
Sep-13-24 03:49PM	Goldman Thinks ZoomInfo Technologies Inc. (ZI) Is A Long-Term AI Stock Set To Rally Eventually (Insider Monkey)
02:50PM	ZoomInfo Technologies (ZI) Faces Investor Backlash After Another Disappointing Earnings Report - Hagens Berman (GlobeNewswire)
12:09PM	ZoomInfo Data Reveals Best and Worst Times of Year to Send Email (Business Wire)
Sep-11-24 01:24PM	ZoomInfo Technologies Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before November 4, 2024 to Discuss Your Rights ZI (GlobeNewswire)
Sep-10-24 03:25PM	ZoomInfo Technologies (ZI) Faces Investor Backlash After Another Disappointing Earnings Report - Hagens Berman (GlobeNewswire)
Sep-04-24 04:32PM	ZoomInfo Technologies Inc. (ZI): An Under The Radar AI Stock You Should Pay Attention To (Insider Monkey)
Aug-14-24 09:00AM	ZoomInfo Wins 2024 TrustRadius Tech Cares Award for Reducing e-Waste in Landfills, Donating Electronics to Those in Need (Business Wire)
09:00AM	Loading…
Aug-13-24 09:00AM	Insiders Buying Walt Disney And 2 Other Stocks (Benzinga) +5.74%
Aug-07-24 09:00AM	ZoomInfo to Participate in Upcoming Investor Conferences (Business Wire) +8.61%
09:00AM	Artificial Intelligence Job Titles Have Tripled Since 2022 According To A New Report From ZoomInfo (Business Wire)
Aug-06-24 04:17PM	These Stocks Moved the Most Today: Palantir, Nvidia, Uber, Caterpillar, CrowdStrike, Lumen, Kenvue, ZoomInfo, and More (Barrons.com) -18.27%
01:56PM	These Stocks Are Moving the Most Today: Palantir, Nvidia, Uber, Caterpillar, CrowdStrike, Lumen, Kenvue, ZoomInfo, and More (Barrons.com)
12:35PM	Why ZoomInfo (ZI) Shares Are Falling Today (StockStory)
12:29PM	CSX, Caterpillar rise; ZoomInfo, Teradata fall, Tuesday, 8/6/2024 (Associated Press Finance)
10:34AM	Stocks to Watch Tuesday: Uber, Caterpillar, Palantir, Lucid (The Wall Street Journal)
09:35AM	Nvidia, Crowdstrike upgraded: Wall Street's top analyst calls (The Fly)
09:25AM	Q2 2024 Zoominfo Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
04:32AM	ZoomInfo stock falls 16% on weak guidance, CFO transition; Analysts downgrade (Investing.com)
Aug-05-24 10:15PM	ZoomInfo Technologies (ZI) Q2 2024 Earnings Call Transcript (Motley Fool) -5.86%
05:20PM	ZoomInfo (ZI) Q2 Earnings and Revenues Lag Estimates (Zacks)
04:41PM	ZoomInfo (NASDAQ:ZI) Misses Q2 Revenue Estimates, Stock Drops 12% (StockStory)
04:22PM	ZoomInfo: Q2 Earnings Snapshot (Associated Press Finance)
04:06PM	Loading…
04:06PM	ZoomInfo Announces Board of Directors Appointments (Business Wire)
04:05PM	ZoomInfo Announces Second Quarter 2024 Financial Results (Business Wire)
04:05PM	ZoomInfo Announces CFO Transition (Business Wire)
Aug-04-24 03:02AM	ZoomInfo (ZI) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Jul-26-24 04:02AM	Q1 Earnings Highs And Lows: Salesforce (NYSE:CRM) Vs The Rest Of The Sales Software Stocks (StockStory)
Jul-25-24 01:17PM	ZoomInfo alum raises $15M for startup that builds AI sales engineers (TechCrunch)
03:39AM	Sales Software Stocks Q1 Teardown: ZoomInfo (NASDAQ:ZI) Vs The Rest (StockStory)
Jul-18-24 09:00AM	ZoomInfo to Report Financial Results for Second Quarter 2024 on August 5, 2024 (Business Wire)
Jul-08-24 03:43AM	Winners And Losers Of Q1: Freshworks (NASDAQ:FRSH) Vs The Rest Of The Sales Software Stocks (StockStory)
Jul-02-24 04:30PM	ZoomInfo Named Top Solution in 30 Grids in G2s Summer 2024 Reports (Business Wire)
Jun-24-24 06:02PM	Crypto under pressure, Good Buy or Goodbye: Market Domination (Yahoo Finance Video)
04:29PM	HubSpot is a stock to invest in, zoom from ZoomInfo: Analyst (Yahoo Finance Video)
09:00AM	ZoomInfo Achieves First-of-Its-Kind Responsible AI Certification from TrustArc (Business Wire)
Jun-20-24 06:16AM	Q1 Sales Software Earnings: HubSpot (NYSE:HUBS) Earns Top Marks (StockStory)
Jun-05-24 09:30AM	Billionaires Are Selling Nvidia and Buying These 3 Stocks Instead (InvestorPlace)
May-22-24 09:00AM	ZoomInfo Releases AI-Powered ZoomInfo Copilot to Make Every Seller Your Best Seller (Business Wire)
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)
May-13-24 09:00AM	ZoomInfo to Participate in Upcoming Investor Conferences (Business Wire)
May-10-24 06:47PM	Why ZoomInfo Technologies Stock Plunged by 21% This Week (Motley Fool)
May-09-24 09:00AM	ZoomInfo Sweeps All Six Eligible Categories in TrustRadius Top Rated Awards for Customer Satisfaction (Business Wire)
May-08-24 12:55PM	ZoomInfo Technologies Declines Following Analyst Actions Post Q1 Earnings (MT Newswires) -24.22%
12:22PM	Why ZoomInfo (ZI) Stock Is Down Today (StockStory)
11:56AM	ZoomInfo Technologies Inc. (NASDAQ:ZI) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:27AM	Wells Fargo Cuts Price Target on ZoomInfo Technologies to $21 From $28, Maintains Overweight Rating (MT Newswires)
10:32AM	UBS Adjusts Price Target on ZoomInfo Technologies to $16 From $19, Maintains Neutral Rating (MT Newswires)
10:26AM	Stifel Adjusts Price Target on ZoomInfo Technologies to $20 From $24, Maintains Buy Rating (MT Newswires)
10:22AM	ZoomInfo Technologies Stock Is Spiraling. Earnings Werent the Problem. (Barrons.com)
09:34AM	Deutsche Bank Adjusts ZoomInfo Technologies Price Target to $17 From $20, Maintains Hold Rating (MT Newswires)
08:57AM	Truist Securities Cuts Price Target on ZoomInfo Technologies to $16 From $20, Maintains Hold Rating (MT Newswires)
08:14AM	Q1 2024 Zoominfo Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
08:03AM	Morgan Stanley Lowers Price Target on ZoomInfo Technologies to $16 From $18, Keeps Equalweight Rating (MT Newswires)
07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
06:47AM	Mizuho Downgrades ZoomInfo Technologies to Neutral From Buy, Cuts Price Target to $14 From $23 (MT Newswires)
06:45AM	Piper Sandler Downgrades ZoomInfo Technologies to Neutral From Overweight, Cuts Price Target to $15 From $24 (MT Newswires)
06:45AM	Goldman Sachs Downgrades ZoomInfo Technologies to Sell From Neutral, Cuts Price Target to $12 From $19.50 (MT Newswires)
May-07-24 10:30PM	ZoomInfo Technologies (ZI) Q1 2024 Earnings Call Transcript (Motley Fool)
05:48PM	ZoomInfo Technologies Inc (ZI) Q1 2024 Earnings: Revenue Growth and Strategic Achievements (GuruFocus.com)
05:38PM	ZoomInfo Q1 Adjusted Earnings, Revenue Rise, Sets Guidance -- Shares Fall After-Hours (MT Newswires)
05:15PM	ZoomInfo (ZI) Q1 Earnings and Revenues Surpass Estimates (Zacks)
04:27PM	ZoomInfo (NASDAQ:ZI) Posts Q1 Sales In Line With Estimates But Stock Drops 15.9% (StockStory)
04:15PM	ZoomInfo: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	ZoomInfo Announces First Quarter 2024 Financial Results (Business Wire)
May-06-24 03:07AM	ZoomInfo (ZI) Reports Earnings Tomorrow: What To Expect (StockStory)
Apr-15-24 12:00PM	ZoomInfo (ZI) Upgraded to Buy: Here's Why (Zacks)
09:00AM	ZoomInfo to Report Financial Results for First Quarter 2024 on May 7, 2024 (Business Wire)
Apr-10-24 09:00AM	ZoomInfo Named Top Enterprise Solution in 10 Categories in G2s Spring 2024 Reports (Business Wire)
Apr-09-24 09:00AM	ZoomInfo Wins Two Google Cloud Technology Partner of the Year Awards (Business Wire)
07:00AM	ZoomInfo and TrustRadius Partner To End Revenue Anxiety (PR Newswire)
Apr-02-24 04:30AM	Spotting Winners: ZoomInfo (NASDAQ:ZI) And Sales Software Stocks In Q4 (StockStory)
Apr-01-24 07:22AM	Q4 Rundown: Freshworks (NASDAQ:FRSH) Vs Other Sales Software Stocks (StockStory)
Mar-13-24 12:04PM	ZoomInfo Named a Leader Among B2B Marketing and Sales Data Providers by Independent Research Firm (Business Wire)
Mar-05-24 05:28AM	Baron Global Advantage Fund Thinks it Sold ZoomInfo Technologies (ZI) 'Too Slowly (Insider Monkey)
Feb-26-24 05:45PM	7 Stocks That Googles Updated AI Wants You to Buy (InvestorPlace)
Feb-20-24 09:00AM	ZoomInfo to Participate in Upcoming Investor Conferences (Business Wire)
Feb-15-24 05:00PM	ZoomInfo Releases Its 2023 Sustainability Report (Business Wire)
Feb-13-24 08:03PM	Why ZoomInfo Technologies Stock Soared Today (Motley Fool) +14.36%
04:24PM	These Stocks Moved the Most Today: Shopify, JetBlue, Arm, ZoomInfo, Tripadvisor, WK Kellogg, Ecolab, Biogen, and More (Barrons.com)
01:14PM	These Stocks Are Moving the Most Today (Barrons.com)
01:14PM	Valuation Too Attractive to Ignore: Jefferies Suggests 2 Software Stocks to Buy (TipRanks)
01:13PM	These Stocks Are Moving the Most Today: Shopify, JetBlue, Arm, ZoomInfo, Tripadvisor, WK Kellogg, Ecolab, Biogen, and More (Barrons.com)
12:44PM	Why ZoomInfo (ZI) Stock Is Up Today (StockStory)
10:08AM	ZoomInfo Stock Is Soaring After Earnings. An AI Solution Is One Reason Why. (Barrons.com)
08:55AM	Q4 2023 Zoominfo Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
08:46AM	ZoomInfo Technologies Inc. (NASDAQ:ZI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-12-24 09:15PM	ZoomInfo Technologies (ZI) Q4 2023 Earnings Call Transcript (Motley Fool)
05:44PM	Avis, Arista Networks, ZoomInfo: After-Hours Earnings (Yahoo Finance Video)
05:15PM	ZoomInfo (ZI) Q4 Earnings and Revenues Top Estimates (Zacks)
04:38PM	ZoomInfo Technologies Inc (ZI) Reports Steady Growth in Q4 and Full-Year 2023 Earnings (GuruFocus.com)
04:26PM	ZoomInfo: Q4 Earnings Snapshot (Associated Press Finance)
04:13PM	ZoomInfo (NASDAQ:ZI) Posts Better-Than-Expected Sales In Q4, Stock Jumps 10.2% (StockStory)

ZoomInfo Technologies, Inc. is a holding company, which engages in the provision of a cloud-based platform that offers information on organizations and professionals for sales and marketing teams. It offers sales leadership, sales development, marketing, and demand generation, sales and marketing operations, and recruiting. The company was founded by Henry L. Schuck and Kirk N. Brown in 2007 and is headquartered in Vancouver, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dasdan Ali	Chief Technology Officer	Sep 06 '24	Sale	9.63	4,898	47,184	103,963	Sep 10 04:18 PM
ALI DASDAN	Officer	Sep 06 '24	Proposed Sale	9.94	4,898	48,686		Sep 06 04:19 PM
Schuck Henry	Chief Executive Officer	Aug 07 '24	Buy	8.49	1,500,000	12,736,650	11,788,001	Aug 09 04:41 PM
Hyzer Peter Cameron	Chief Financial Officer	Jul 09 '24	Sale	12.37	7,500	92,775	1,316,518	Jul 11 04:38 PM
Hyzer Peter Cameron	Chief Financial Officer	Jun 13 '24	Sale	12.78	7,500	95,850	1,279,023	Jun 17 04:15 PM
MADER MARK PATRICK	Director	Jun 13 '24	Sale	12.78	3,112	39,771	17,622	Jun 17 04:15 PM
Dasdan Ali	Chief Technology Officer	Jun 04 '24	Sale	11.90	5,862	69,744	87,540	Jun 04 07:01 PM
Dasdan Ali	Chief Technology Officer	Mar 04 '24	Sale	16.56	6,334	104,916	69,954	Mar 05 04:45 PM
Dasdan Ali	Chief Technology Officer	Dec 04 '23	Sale	14.69	5,007	73,577	50,953	Dec 05 04:57 PM

JSPR

Jasper Therapeutics Inc

MKSI

MKS Instruments, Inc.

VERA

Vera Therapeutics Inc

ZI

ZoomInfo Technologies Inc.

Upgrade your FINVIZ experience